Trials / Conditions / Post-essential Thrombocythemia Myelofibrosis (PET-MF)
Post-essential Thrombocythemia Myelofibrosis (PET-MF)
3 registered clinical trials studyying Post-essential Thrombocythemia Myelofibrosis (PET-MF) — 2 currently recruiting.
| Status | Trial | Sponsor | Phase |
|---|---|---|---|
| Recruiting | A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF) NCT07357727 | Novartis Pharmaceuticals | Phase 3 |
| Recruiting | MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People NCT07362225 | MPN Research Foundation | — |
| Completed | Bomedemstat (IMG-7289/MK-3543) in Participants With Myelofibrosis (IMG-7289-CTP-102/MK-3543-002) NCT03136185 | Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA) | Phase 1 / Phase 2 |